Literature DB >> 11555609

Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.

W W Li1, N Takahashi, S Jhanwar, C Cordon-Cardo, Y Elisseyeff, J Jimeno, G Faircloth, J R Bertino.   

Abstract

The cytotoxic effects of ecteinascidin-743(ET-743), a novel marine natural product, were evaluated and compared with that of clinically used anticancer agents methotrexate, doxorubicin, etoposide, and paclitaxel in eight human soft tissue sarcoma (STS) cell lines. HT-1080, a fibrosarcoma cell line, and HS-42, a malignant mesodermal cell line, were the most sensitive of the cell lines to methotrexate, doxorubicin, etoposide, and paclitaxel. Other cell lines (IC50s) varied considerably and were more resistant to these agents. ET-743 was more potent than any of these agents, with IC50s in the pM range in all of the cell lines. Cytotoxicity of ET-743 was dose- and time-related (4-72 h exposure). Cytotoxic concentrations of ET-743 produced a S/G2 block in all of the cell lines tested. Three colon adenocarcinoma cell lines, HCT-8, HT-29, and HCT-116, and one breast cancer cell line, MCF-7, were 1-2 logs less sensitive to ET-743 than the STS cell lines. Cell lines were also characterized as to expression of oncogenes and tumor suppressor genes to attempt to correlate sensitivity of these cell lines to ET-743 and other chemotherapeutic agents. All of the cell lines except M8805, a malignant fibrous histiocytoma cell line, had mutations in p53 and/or overexpressed the MDM2 protein. Only HS-18, a liposarcoma cell line, lacked expression of the retinoblastoma protein. None of the cell lines had detectable expression of P-glycoprotein as measured by immunohistochemistry. ET-743 is an extremely potent cytotoxic agent against human STS cell lines and is being evaluated as an antitumor agent in this disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11555609

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.

Authors:  Lia Gore; E Rivera; M Basche; S L Moulder-Thompson; J Li; S Eppers; S Grolnic; C O'Bryant; D Cleere; Y A Elsayed; S G Eckhardt
Journal:  Invest New Drugs       Date:  2011-09-20       Impact factor: 3.850

2.  Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.

Authors:  M Tavecchio; C Natoli; P Ubezio; E Erba; M D'Incalci
Journal:  Cell Prolif       Date:  2007-12       Impact factor: 6.831

3.  Characterization of a novel radiation-induced sarcoma cell line.

Authors:  Julie Lang; Weizhu Zhu; Brandon Nokes; Grishma Sheth; Petr Novak; Laura Fuchs; George Watts; Bernard Futscher; Neal Mineyev; Alexander Ring; Lauren LeBeau; Ray Nagle; Lee Cranmer
Journal:  J Surg Oncol       Date:  2015-02-02       Impact factor: 3.454

Review 4.  Trabectedin: novel insights in the treatment of advanced sarcoma.

Authors:  Jay Patrick Lopez; Csaba Gajdos; Anthony Elias
Journal:  Curr Oncol Rep       Date:  2014-06       Impact factor: 5.075

Review 5.  Enriching cancer pharmacology with drugs of marine origin.

Authors:  Paula C Jimenez; Diego V Wilke; Paola C Branco; Anelize Bauermeister; Paula Rezende-Teixeira; Susana P Gaudêncio; Leticia V Costa-Lotufo
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

6.  Role of trabectedin in the treatment of soft tissue sarcoma.

Authors:  Alexandre Christinat; Serge Leyvraz
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

Review 7.  Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.

Authors:  Natalie J Carter; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Characterization and comparison of the properties of sarcoma cell lines in vitro and in vivo.

Authors:  Joslyn Mills; Tulio Matos; Elizabeth Charytonowicz; Todd Hricik; Mireia Castillo-Martin; Fabrizio Remotti; Francis Y Lee; Igor Matushansky
Journal:  Hum Cell       Date:  2009-11       Impact factor: 4.174

9.  A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.

Authors:  M von Mehren; R J Schilder; J D Cheng; E Temmer; T M Cardoso; F G Renshaw; E Bayever; P Zannikos; Z Yuan; R B Cohen
Journal:  Ann Oncol       Date:  2008-05-22       Impact factor: 32.976

10.  Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.

Authors:  Gregory J Aune; Kazutaka Takagi; Olivier Sordet; Josée Guirouilh-Barbat; Smitha Antony; Vilhelm A Bohr; Yves Pommier
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.